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OBJECTIVE—Type 1 diabetes arises from the actions of mul-
tiple genetic and environmental risk factors. Considerable suc-
cess at identifying common genetic variants that contribute to
type 1 diabetes risk has come from genetic association (primarily
case-control) studies. However, such studies have limited power
to detect genes containing multiple rare variants that contribute
signiﬁcantly to disease risk.
RESEARCH DESIGN AND METHODS—The Type 1 Diabetes
Genetics Consortium (T1DGC) has assembled a collection of
2,496 multiplex type 1 diabetic families from nine geographical
regions containing 2,658 affected sib-pairs (ASPs). We describe
the results of a genome-wide scan for linkage to type 1 diabetes
in the T1DGC family collection.
RESULTS—Signiﬁcant evidence of linkage to type 1 diabetes
was conﬁrmed at the HLA region on chromosome 6p21.3 (loga-
rithm of odds [LOD]  213.2). There was further evidence of
linkage to type 1 diabetes on 6q that could not be accounted for
by the major linkage signal at the HLA class II loci on chromo-
some 6p21. Suggestive evidence of linkage (LOD 2.2) was
observed near CTLA4 on chromosome 2q32.3 (LOD  3.28) and
near INS (LOD  3.16) on chromosome 11p15.5. Some evidence
for linkage was also detected at two regions on chromosome 19
(LOD  2.84 and 2.54).
CONCLUSIONS—Five non–HLA chromosome regions showed
some evidence of linkage to type 1 diabetes. A number of
previously proposed type 1 diabetes susceptibility loci, based on
smaller ASP numbers, showed limited or no evidence of linkage
to disease. Low-frequency susceptibility variants or clusters of
loci with common alleles could contribute to the linkage signals
observed. Diabetes 58:1018–1022, 2009
T
ype 1 diabetes develops when the insulin-secret-
ing -cells in the pancreas are depleted by an
autoimmune process of unknown origin. Diagno-
sis occurs when sufﬁcient -cell mass is lost that
blood glucose levels cannot be maintained in the physio-
logic range. Although insulin treatment for type 1 diabetes
is life saving, development of effective preventive thera-
pies could be enhanced by improved prediction and a
better understanding of the underlying disease mecha-
nism, particularly events occurring during the extended
preclinical period. Such considerations have motivated
studies directed toward identifying the genetic risk factors
that contribute to the disorder that might provide novel
insights into disease etiology and targets for preventive
therapy.
A number of genome-wide scans for linkage to type 1
diabetes have been reported (1–7). All such studies con-
sistently ﬁnd evidence of linkage of type 1 diabetes to the
HLA region on chromosome 6p21. An additional 15–20
regions with evidence of linkage to type 1 diabetes have
been reported, but many of these regions have not been
reproduced in independent studies. Several attempts have
been made to address this problem through merging of
datasets from different smaller studies (5,7), but differ-
ences in marker sets and allele coding have limited the
power of these efforts.
To address issues of sample size and consistency and to
clarify the evidence for linkage to type 1 diabetes, the Type
1 Diabetes Genetics Consortium (T1DGC) has conducted
the largest affected sib-pair (ASP) linkage study in type 1
diabetes to date. This study includes many (n  1,189) of
the type 1 diabetes families used in previous smaller
linkage studies, but the majority of families (n  1,307) are
newly recruited. More importantly, all samples, both ret-
rospective and newly recruited, were independently geno-
typed expressly for this study at a single laboratory using
a single platform and a common marker set. Analyses of
these data provided evidence for linkage to type 1 diabetes
in six regions on four different chromosomes.
RESEARCH DESIGN AND METHODS
The families included in the analyses were ascertained from nine different
sources: the four T1DGC regional networks of Asia-Paciﬁc (n  228), Europe
(n  585), North America (n  370), and the U.K. (n  124); the Diabetes UK
Warren 1 Repository (n  429); the Human Biological Data Interchange
repository (n  424); the Joslin Diabetes Center (n  112); the Steno Diabetes
Center (n  146); and Sardinia (n  78). To be included in the study, a family
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1018 DIABETES, VOL. 58, APRIL 2009had to have at least one ASP available for sampling; availability of one or both
biological parents was preferred but not required. An individual was desig-
nated as affected if he or she had documented type 1 diabetes with onset at
35 years of age, had used insulin within 6 months of diagnosis, and had no
concomitant disease or disorder associated with diabetes. A total of 2,496
families were genotyped. Most families, 2,287 (91.6%), had exactly two
affected full siblings, 101 (4.0%) had three, and 7 (0.3%) had four or more.
Among 2,657 ASPs in total, both parents were available for 69.6% of the ASPs,
18.9% had only a single parent available, and 11.6% had neither parent
available. A few extended pedigrees also provided 13 affected half-sib pairs
and 22 affected-affected avuncular pairs.
Genotyping. Genotyping was carried out at the Center for Inherited Disease
Research (CIDR) using the Illumina Human Linkage-12 Genotyping Beadchip,
which contains 6,090 single nucleotide polymorphisms with an average
genome-wide spacing of 0.58 cM.
Statistical analysis. Before statistical genetic analyses, genotype data were
evaluated for Mendelian errors using PedCheck (8). PREST (9) was used to
estimate the likelihood of each speciﬁed relationship in pedigrees given the
genotyping information. Based on these analyses, 43 families were removed
from further analysis due to the presence of a duplicate family, a duplicate
sample within the family, nonresolvable family errors, or missing genotype
information. Merlin (10) was used to identify and resolve inconsistencies
within families. Finally, 199 affected individuals who were not genotyped were
removed from the analysis. The Kong and Cox linear nonparametric linkage
(NPL) model (11) implemented in Merlin was used for the NPL link-
age analysis. Marker-marker linkage disequilibrium was modeled in the
linkage analysis using the maximum-likelihood clustered marker approach
implemented in Merlin with a cutoff of r
2  0.5.
RESULTS
Figure 1 shows the results of the genome-wide analysis for
linkage to type 1 diabetes in the entire T1DGC family
collection. The average information content across all
chromosomes was 0.924 and ranged from 0.904 on chro-
mosome 20 to 0.939 on chromosomes six and X. Table 1
lists the regions where evidence for linkage exceeded the
threshold for suggestive linkage (logarithm of odds [LOD]
2.2) in an ASP linkage study. The HLA region on chro-
mosome 6p21.3 was the only region to display signiﬁcant
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FIG. 1. Genome-wide evidence for linkage to type 1 diabetes. Evidence for linkage was evaluated using Merlin, and LOD scores were calculated
using the Kong and Cox linear NPL model (10,11). LOD scores are plotted on the vertical axis versus chromosomal position on the horizontal axis.
LOD scores at region 15.5–110.5 cM on chromosome 6 are larger than four and not shown. The dotted horizontal line indicates a LOD of 2.2. The
dashed line indicates a LOD of 3.6.
TABLE 1
Regions with suggestive or signiﬁcant evidence of linkage to type 1 diabetes
Chromosome Position (cM) LOD P LOD-1 support interval Flanking markers*
2 194.25 3.28 5.0  10
5 191.3–197.8 rs1882395/rs1369842
6 52.0 213.2 8.0  10
216 51.0–52.5 rs11908/rs412735
11 2.5 3.16 7.0  10
5 0–8.5 rs741737/rs1609812
19 9.5 2.84 0.00015 7.5–26 rs887270/rs1044250
19 58.0 2.54 0.0003 52–63 rs1019937/rs1878926
*Genotyped markers bounding the LOD-1 support interval.
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additional regions provided suggestive evidence of link-
age. These included a region on chromosome 2q (LOD 
3.28), where there have been multiple past reports of
linkage to type 1 diabetes, and the region surrounding the
insulin gene at 11p15.5 (LOD  3.16) that has been
previously implicated in type 1 diabetes susceptibility by
both linkage and association studies. The remaining two
regions were on chromosome 19 (LOD  2.84 and 2.54)
and are separated from each other by 48.5 cM; evidence of
linkage to chromosome 19 has been reported before but
not to any level of conﬁdence that justiﬁed speciﬁc atten-
tion. Other previously reported type 1 diabetes loci, which
quite often were given type 1 diabetes designations, were
not conﬁrmed in the current study (Table 2).
When considering evidence for linkage to type 1 diabe-
tes on chromosome 6 that might possibly be due to loci
other than the classic HLA genes, it was necessary to take
into account the signiﬁcant allele sharing at HLA, where
LOD scores 3.6 were detected over an interval of 100
cM surrounding the locus. We searched for evidence of
additional type 1 diabetes risk loci by calculating expected
LOD (ELOD) scores based upon allele sharing at HLA
along the length of chromosome 6 (supplementary Fig. 1,
available in an online appendix at http://diabetes.diabetes
journals.org/cgi/content/full/db08-1551/DC1). The observed
LOD score exceeded the ELOD by 3.6 in three regions. One
of these regions, from 81.5 to 101.5 cM (maximum LOD 
ELOD  10.8), overlapped with the location of the previ-
ously reported IDDM15 locus (6,12).
DISCUSSION
The T1DGC family collection includes the largest number
of ASPs to be tested for linkage to type 1 diabetes in a
genome-wide scan yet provides suggestive or signiﬁcant
evidence for only ﬁve loci linked to type 1 diabetes. In light
of the numerous previous reports of loci linked to type 1
diabetes, we considered the relationship between the
ﬁndings here and prior studies (Table 2).
The majority of studies, as in our current report, have
observed signiﬁcant evidence of linkage to type 1 diabetes
at HLA, and there is well-conﬁrmed evidence of disease
association in the same region. Several additional loci on
chromosome 6 (IDDM5, IDDM8, and IDDM15) have been
proposed based on previous linkage studies (1,13,14). The
current study provides little support for either IDDM5 or
IDDM8 (Table 2). However, we did obtain a regional
maximum LOD of 5.43, at 190.0 cM on chromosome 6q27,
where IDDM8 was previously localized (13) when linkage
disequilibrium was not modeled in the analysis. This
region is characterized by a relatively strong intermarker
linkage disequilibrium, which might explain this and pre-
vious reports of linkage in this region.
An additional region on chromosome 6q provided evi-
dence for linkage to type 1 diabetes after adjusting for the
effect of allele sharing at HLA. Previous studies have
tested for linkage at IDDM15, which is located in this
region, by calculating the expected LOD score at IDDM15
based upon the observed identical-by-descent (IBD) shar-
ing at HLA and the recombination fraction between HLA
and D6S283 (7,12). The excess of the observed IBD
sharing compared with that which was expected was then
used as a measure of the independent contribution of
IDDM15. Applying this approach to the current dataset
identiﬁed a broad (20 cM) region where the adjusted LOD
exceeds 3.6. Uncertainties remain as to the precise location
of IDDM15 because male and female recombination maps
differ substantially in this region. Nevertheless, this region of
increased LODs, after adjusting for the contribution of allele
sharing at HLA, provides support for the existence of an
additional linkage to type 1 diabetes in this region.
Chromosome 2q contains two conﬁrmed type 1 diabetes
risk loci near the IFIH1 and CTLA4 genes identiﬁed by
association and three proposed loci (IDDM7, IDDM12,
and IDDM13) for which suggestive evidence of linkage has
been observed in some, but not all, studies (15–17). In the
current report, there was no support for multiple distinct
loci; suggestive evidence of linkage was observed in the
2q32.3 region, approximately midway between the previ-
TABLE 2
Evidence for linkage in regions previously reported to harbor IDDM loci
Locus Chromosome Deﬁned by marker(s) Marker tested LOD P
IDDM1 6p21.3 HLA-DQ1 rs1019937 213.2 8.0  10
216
IDDM2 11p15.5 INS-VNTR rs1004446 3.09 0.00008
IDDM3 15q26 D15S107 rs906310 0.00 0.6
IDDM4 11q13 D11S1917 rs923346 0.87 0.02
IDDM5 6q25 ESR rs11902 0.00 0.5
IDDM6 18q D18S64 rs1943418 0.68 0.04
IDDM7 2q31 D2S152 rs696092 1.91 0.002
IDDM8 6q27 D6S264 rs6910121 0.45 0.07
IDDM9 3q21-25 D3S1303 rs1983380 0.40 0.09
IDDM10 10cen D10S193 rs959629 1.07 0.013
IDDM11 14q24.3 D14S67 rs1012921 0.13 0.2
IDDM12 2q33 CTLA4 rs1947983 1.05 0.014
IDDM13 2q34 IGFBP2 rs1851328 0.63 0.04
IDDM15 6q D6S283 rs2207958 5.99* 7.5  10
8
IDDM16 14q32.3 D14S293 rs872945 0.05 0.3
IDDM17 10q25 D10S592 rs151603 0.16 0.2
IDDM18 5q33-34 IL12B rs270664 0.01 0.4
1q42 D1S1617 rs342817 0.00 0.5
16q22-24 D16S3098 rs1037973 1.24 0.008
*Not corrected for allele sharing at IDDM1. Adjustment based upon the expected LOD at D6S283 and the recombination fraction with HLA
yields an adjusted LOD of 2.7.
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locus at 11p15.5 is also well established as a risk locus for
type 1 diabetes (18). Previous studies have provided
signiﬁcant evidence for both association and linkage to
this site. The current study also ﬁnds suggestive evidence
of linkage in this region.
Two regions on chromosome 19 displayed suggestive
evidence of linkage to type 1 diabetes, which, given our
sample sizes and marker map, is the most interesting data yet
for this chromosome. So far, no associations with genome-
wide signiﬁcance have been reported in these regions.
Recently, genome-wide association (GWA) studies have
identiﬁed at least 18 genomic regions with signiﬁcant
evidence of association to type 1 diabetes, but the majority
of these loci, although common in the population, have
relatively modest individual effects on risk (e.g., odds
ratios [ORs] of 1.1–1.3) (19–22). Linkage studies are not
optimal for detecting such loci where the risk alleles are
common and have small individual effect sizes. Thus, it is
not surprising that none of these newly identiﬁed loci from
GWA studies fall within regions of even suggestive linkage
in the current study. Several of our linkage peaks do
include loci previously detected by association, but these
tend to have large effects on risk such as HLA (OR 11.4)
(23) or INS (2.38) (18).
The large sample size studied here, 2,658 ASPs from
2,496 families, provided us with unprecedented power to
detect linkage to type 1 diabetes across the genome. While
we detected one locus with signiﬁcant evidence of linkage,
and ﬁve more regions with suggestive evidence, our study
provides little support for the majority of previously
proposed type 1 diabetes loci. Our power to detect evi-
dence of linkage to type 1 diabetes comes at a cost; the low
frequency of families with multiple affected siblings re-
quired a world-wide recruitment effort. Therefore, we
cannot exclude the possibility that loci with strong effects
in particular populations might be obscured in the current
analysis. For example, LOD  3.21 was observed at 66.1
cM on chromosome 17 in the 370 T1DGC families re-
cruited by the North American network, whereas no
linkage was detected in the other eight populations (LOD
scores ranging from 0.62 to 0.30).
In summary, the evidence for independent major gene
effects in type 1 diabetes detectable by linkage (e.g., rare
variants), which are shared across populations, appears to
be limited to a few genes in the HLA complex: INS, CTLA4,
IDDM15, and possibly two regions on chromosomes 19.
The combination of these putative rare variant effects with
common variants of smaller effect size, more readily
detected by association-based approaches, accounts for
the majority of risk for type 1 diabetes of which HLA class
II alleles are by far the major contributor. Identiﬁcation of
candidate genes and variants in these and other regions will
help to clarify the biochemical pathways and mechanisms
that contribute to risk for this common autoimmune disease.
The substantial collection of biospecimens and data assem-
bled by the T1DGC, and available to diabetes researchers
(www.t1dgc.org and www.t1dbase.org), should be an impor-
tant resource for further characterizing those genomic re-
gions identiﬁed by either linkage or association approaches
as contributing to risk for type 1 diabetes.
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